title: Expression and clinical significance of multidrug resistance proteins in brain tumors.
abstract: BACKGROUND
  To investigate the mechanisms of multidrug resistance of brain tumors, to identify the site of cellular expression of P-gp in human brains in situ and to morphologically determine whether an association may exist between P-gp and caveolin-1.
  
  
  METHODS
  Immunohistochemistry was used to detect the expression and location of P-glycoprotein (P-gp), multidrug resistance-associated protein (MDR), lung resistance-related protein (LRP), topoisomerase II (Topo II) and glutathione-S-π (GST-π) in 30 patient tumor tissues and 5 normal brain tissues. The sections were subjected to double labeling for P-gp (TRITC labeled) and caveolin-1 (FITC labeled). The location and characteristics of expression of the two proteins in the blood brain barrier(BBB) was observed using a laser scanning microscope.
  
  
  RESULTS
  High expression of P-gp was detected in vessel walls and the tissue surrounding the vessels. However, expression of P-gp was low in tumor cells. The expression of the other 4 multidrug resistance proteins was not observed in the vessel walls. Laser scanning microscopy showed P-gp and caveolin-1 co-expression: the two proteins co-localized either in the luminal endothelial compartment or at the border of the luminal/abluminal compartments.
  
  
  CONCLUSIONS
  Chemotherapeutics drugs are interrupted in the end-feet of neuroepithelial cells of the BBB by P-gp, which weakens the chemotherapeutic effect. P-gp marks the BBB, and the transporter is localized in the luminal endothelial compartment where it co-localizes with caveolin-1.
authors.affiliation: Department of Oncology, Children's Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Guo
authors.forename: Jin
authors.initials: J
authors.lastname: Zhu
authors.forename: Lihua
authors.initials: L
authors.lastname: Zhao
authors.forename: Qing
authors.initials: Q
authors.lastname: Luo
authors.forename: Xianqing
authors.initials: X
authors.lastname: Jin
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis*; D001812:Blood-Brain Barrier / Q000737:chemistry; D001932:Brain Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D051242:Caveolin 1 / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D002681:China; D004250:DNA Topoisomerases, Type II / Q000032:analysis; D019008:Drug Resistance, Neoplasm; D042783:Endothelial Cells / Q000737:chemistry; D005260:Female; D051549:Glutathione S-Transferase pi / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D018613:Microscopy, Confocal; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000032:analysis; D009367:Neoplasm Staging; D009457:Neuroglia / Q000737:chemistry; D020394:Vault Ribonucleoprotein Particles / Q000032:analysis; D000099187:Major Vault Protein
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D051242:Caveolin 1; D004250:DNA Topoisomerases, Type II; D051549:Glutathione S-Transferase pi; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein; C513055:ABCB1 protein, human; C495540:CAV1 protein, human; C496556:GSTP1 protein, human
references.citation: Med Sci Monit. 2004 Jan;10(1):RA5-14
references.pmid: 14704647
references.citation: Glycoconj J. 2000 Mar-Apr;17(3 -4):253-9
references.pmid: 11201798
references.citation: Eur Neuropsychopharmacol. 2008 Mar;18(3):157-69
references.pmid: 17683917
references.citation: Vascul Pharmacol. 2002 Jun;38(6):339-48
references.pmid: 12529928
references.citation: Biochemistry. 1997 Sep 9;36(36):10944-53
references.pmid: 9283086
references.citation: Brain Res. 1999 Feb 20;819(1-2):143-6
references.pmid: 10082869
references.citation: Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10104-8
references.pmid: 7479734
references.citation: J Neurochem. 1997 Mar;68(3):1278-85
references.pmid: 9048775
references.citation: Cancer Treat Rev. 2000 Dec;26(6):449-62
references.pmid: 11139374
references.citation: Neuroreport. 2003 Nov 14;14(16):2041-6
references.pmid: 14600494
references.citation: FEBS Lett. 2000 Jan 28;466(2-3):219-24
references.pmid: 10682831
references.citation: Biochem Biophys Res Commun. 2008 Aug 1;372(3):440-6
references.pmid: 18485890
references.citation: J Neurochem. 2004 May;89(3):788-800
references.pmid: 15086534
references.citation: Curr Drug Metab. 2003 Aug;4(4):272-91
references.pmid: 12871045
references.citation: Biochim Biophys Acta. 2005 Dec 30;1746(3):334-48
references.pmid: 16214243
references.citation: Adv Drug Deliv Rev. 2003 Jan 21;55(1):83-105
references.pmid: 12535575
references.citation: Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):953-65
references.pmid: 20504109
references.citation: J Histochem Cytochem. 2002 Dec;50(12):1671-6
references.pmid: 12486090
references.citation: Trends Cell Biol. 2010 Apr;20(4):177-86
references.pmid: 20153650
references.citation: Biochem Biophys Res Commun. 2001 Mar 2;281(3):827-34
references.pmid: 11237734